Tenascin-C patterns and splice variants in actinic keratosis and cutaneous squamous cell carcinoma

British Journal of Dermatology

Volumn 155, Issue 4, 2006, Pages 763-770

  Dang, C ^a   Gottschling, M ^a   Roewert, J ^a   Forschner, T ^a   Stockfleth, E ^a   Nindl, I ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Actinic keratosis; Cutaneous squamous cell carcinoma; Immunohistochemistry; Quantitative real time reverse transcription polymerase chain reaction; Tenascin C; Tenascin C splice variants

Indexed keywords

SCLEROPROTEIN; TENASCIN;

ACTINIC KERATOSIS; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUNCH BIOPSY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN CANCER; SOUTHERN BLOTTING; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; BLOTTING, SOUTHERN; CARCINOMA, SQUAMOUS CELL; HUMANS; KERATOSIS; MIDDLE AGED; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN; SKIN NEOPLASMS; TENASCIN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 33748449670     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07401.x     Document Type: Article

References (52)

1. Mackie EJ, Halfter W, Liverani D. Induction of tenascin in healing wounds. J Cell Biol 1988; 107:2757-67.
2. Mackie EJ. Molecules in focus: tenascin-C. Int J Biochem Cell Biol 1997; 29:1133-7.
3. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000; 218:235-59.
4. Jones PL, Jones FS. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 2000; 19:581-96.
5. Järvinen TA, Kannus P, Järvinen TL et al. Tenascin-C in the pathobiology and healing process of musculoskeletal tissue injury. Scand J Med Sci Sports 2000; 10:376-82.
6. Joester A, Faissner A. Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system. J Biol Chem 1999; 274:17144-51.
7. Orend G, Chiquet-Ehrismann R. Adhesion modulation by antiadhesive molecules of the extracellular matrix. Exp Cell Res 2000;261:104-10.
8. Zagzag D, Capo V. Angiogenesis in the central nervous system: a role for vascular endothelial growth factor/vascular permeability factor and tenascin-C. Common molecular effectors in cerebral neoplastic and non-neoplastic 'angiogenic diseases'. Histol Histopathol 2002; 17:301-21.
9. Orend G. Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol 2005; 37:1066-83.
10. Nagase H, Woessner Jr JF. Matrix metalloproteinases. J Biol Chem 1999; 274:21491-4.
11. Kerkelä E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 2003; 12:109-25.
12. Erickson HP, Bourdon MA. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol 1989; 5:71-92.
13. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol 2003; 200:488-99.
14. Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol Histopathol 2004; 19:517-25.
15. Adams M, Jones JL, Walker RA et al. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res 2002; 62:3289-97.
16. Gazzaniga P, Nofroni I, Gandini O et al. Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in bladder and colon cancer. Oncol Rep 2005; 14:1199-202.
17. Jones PL. Extracellular matrix and tenascin-C in pathogenesis of breast cancer. Lancet 2001; 357:1992-4.
18. Riedl S, Kadmon M, Tandara A et al. Tenascin-C tissue concentration in inflammatory and neoplastic diseases of the colon mucosa. Anticancer Res 1997; 17:3165-6.
19. Emoto K, Yamada Y, Sawada H et al. Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 2001; 92:1419-26.
20. Korshunov A, Golanov A, Timirgaz V. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. J Neurol Sci 2000; 177:72-82.
21. Herold-Mende C, Mueller MM, Bonsanto MM et al. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer 2002; 98:362-9.
22. Latijnhouwers MA, de Jongh GJ, Bergers M et al. Expression of tenascin-C splice variants by human skin cells. Arch Dermatol Res 2000; 292:446-54.
23. Ilmonen S, Jahkola T, Turunen JP et al. Tenascin-C in primary malignant melanoma of the skin. Histopathology 2004; 45:405-11.
24. Schalkwijk J, van Vlijmen I, Oosterling B et al. Tenascin expression in hyperproliferative skin diseases. Br J Dermatol 1991; 124:13-20.
25. Tuominen H, Pollanen R, Kallioinen M. Multicellular origin of tenascin in skin tumors - an in situ hybridization study. J Cutan Pathol 1997; 24:590-6.
26. Tuominen H, Kallioinen M. Increased tenascin expression in melanocytic tumors. J Cutan Pathol 1994; 21:424-9.
27. Gulcher JR, Nies DE, Alexakos MJ et al. Structure of the human hexabrachion (tenascin) gene. Proc Natl Acad Sci USA 1991; 88:9438-42.
28. Nies DE, Hemesath TJ, Kim JH et al. The complete cDNA sequence of human hexabrachion (tenascin). A multidomain protein containing unique epidermal growth factor repeats. J Biol Chem 1991; 266:2818-23.
29. Siri A, Carnemolla B, Saginati M et al. Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies. Nucleic Acids Res 1991; 19:525-31.
30. Jang JH, Chung CP. Tenascin-C promotes cell survival by activation of Akt in human chondrosarcoma cell. Cancer Lett 2005; 229:101-5.
31. Prieto AL, Jones FS, Cunningham BA et al. Localization during development of alternatively spliced forms of cytotactin mRNA by in situ hybridization. J Cell Biol 1990; 111:685-98.
32. Derr LB, Chiquet-Ehrismann R, Gandour-Edwards R et al. The expression of tenascin-C with the AD1 variable repeat in embryonic tissues, cell lines and tumors in various vertebrate species. Differentiation 1997; 62:71-82.
33. Borsi L, Carnemolla B, Nicolo G et al. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1992; 52:688-92.
34. Tsunoda T, Inada H, Kalembeyi I et al. Involvement of large tenascin-C splice variants in breast cancer progression. Am J Pathol 2003; 162:1857-67.
35. Hindermann W, Berndt A, Borsi L et al. Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma. J Pathol 1999; 189:475-80.
36. Tseleni-Balafouta S, Gakiopoulou H, Fanourakis G et al. Tenascin-C protein expression and mRNA splice variants in thyroid carcinoma. Exp Mol Pathol 2006; 80:177-82.
37. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; 331:795-7.
38. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ('actinic keratosis'). J Am Acad Dermatol 2000; 42:11-17.
39. Fu W, Cockerell CJ. The actinic (solar) keratosis: a 21st-century perspective. Arch Dermatol 2003; 139:66-70.
40. DePinho RA. The age of cancer. Nature 2000; 408:248-54.
41. Nindl I, Toegl A, Sterry W et al. High sensitivity and reproducibility of immunohistochemistry with microagitation. Arch Dermatol Res 2004; 296:278-81.
42. Tiitta O, Wahlstrom T, Paavonen J et al. Enhanced tenascin expression in cervical and vulvar koilocytotic lesions. Am J Pathol 1992; 141:907-13.
43. Koljonen V, Jahkola T, Tukiainen E et al. Tenascin-C in primary Merkel cell carcinoma. J Clin Pathol 2005; 58:297-300.
44. Lightner VA, Gumkowski F, Bigner DD et al. Tenascin/hexabrachion in human skin: biochemical identification and localization by light and electron microscopy. J Cell Biol 1989; 108:2483-93.
45. Koukoulis GK, Gould VE, Bhattacharyya A et al. Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. Hum Pathol 1991; 22:636-43.
46. Shikata N, Oyaizu T, Andachi H et al. Tenascin expression in normal human adult skin and skin appendage tumours. Virchows Arch 1994; 424:511-16.
47. Latijnhouwers MA, Bergers M, van Bergen BH et al. Tenascin expression during wound healing in human skin. J Pathol 1996; 178:30-35.
48. Katenkamp K, Berndt A, Hindermann W et al. mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma. J Pathol 2004; 203:771-9.
49. Kalembeyi I, Inada H, Nishiura R et al. Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1. Int J Cancer 2003; 105:53-60.
50. Sriramarao P, Bourdon MA. A novel tenascin type III repeat is part of a complex of tenascin mRNA alternative splices. Nucleic Acids Res 1993; 21:163-8.
51. Mighell AJ, Thompson J, Hume WJ et al. Human tenascin-C: identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae. Int J Cancer 1997; 72:236-40.
52. Balza E, Siri A, Ponassi M et al. Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett 1993; 332:39-43.